All News

The partnership will entail a new six-month agreement.

BGS Pharmacy Partners will receive an initial $10 million growth capital commitment from DW Healthcare Partners.

Degree will prepare students to take the national certification examination.

Pharmacies will be consolidated by the end of August.

A research team may have produced a more pure and safer alternative to heparin.

The Pharmacists' Defence Association (PDA) union has launched a stress audit of pharmacists.

They're working together to create an innovative medication therapy management program (MTM) for payers, retailers, pharmacists, and consumers.

Until now, Kansas has used a written logbook system to track the sale of OTC medications containing pseudoephedrine.

Group contends CMS is promoting a less expensive generic substitute.

This is based on results of a new study reported in Mayo Clinic Proceedings.

A new report from Decision Resources found that Florida leads the pack with most untreated Type 2 diabetics who also have drug coverage.

Physicians' negative experience with Exubera, Pfizer/Nektar's inhaled insulin, may slow adoption of new therapies.

CVS is already the largest drug chain in the country.

The purchase is expected to expand the enrollment of the campus by up to 400 students.

That's one of the conclusions of a new survey report by Decision Resources.

The FDA said patients should monitor the injection site.

The drug is administered as a once-daily tablet.

The school and sports physicals cost $25.

Patients who have received any of the following drugs should contact their physician for new prescriptions.

FDA still receiving many adverse incidents about the concurrent administration of the two products.

Recall happened because patches leaking fentanyl gel have been detected.

More than 600 bouquets were sent to the site.

A new machine allows pharmacists to accept disposable sharps from consumers and convert them into compact waste that can be thrown in the trash bin.

A group called the Cancer Prevention Coalition is charging that the Food and Drug Administration is asleep at the wheel regarding sunscreens.

Publications are designed to improve management skills, enhance pharmacists' image, and help reduce stress.

Some confusion exists among the medical community and the general public about the toxicity and resistance among prescription lice treatments.

A pending Federal Trade Commission (FTC) report, expected later this year, may settle the decade-old dispute as to whether authorized generics are legal. With billions of dollars at stake, the loser will undoubtedly challenge the government's decision.

Traditionally, generics industry executives are tight-lipped about their business plans. But Drug Topics managed to corral five industry leaders who opened up about their hopes, fears, and challenges: